Expanding Medtech, Industrial And Defense Applications Will Create New Opportunities

AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
Published
23 Feb 25
Updated
08 Aug 25
AnalystConsensusTarget's Fair Value
US$22.50
12.7% undervalued intrinsic discount
08 Aug
US$19.64
Loading
1Y
14.0%
7D
-3.3%

Author's Valuation

US$22.5

12.7% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 19%

Shared on23 Apr 25
Fair value Decreased 3.86%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 8.12%

AnalystConsensusTarget has decreased revenue growth from 5.5% to 3.9%.

Shared on02 Apr 25
Fair value Increased 0.61%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on13 Mar 25
Fair value Increased 2.70%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.